Histone deacetylase–mediated transcriptional activation reduces proviral loads in HTLV-1–associated myelopathy/tropical spastic paraparesis patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Epigenetic modifications of chromatin may play a role in maintaining viral latency and thus persistence of the human T-lymphotropic virus type 1 (HTLV-1), which is responsible for HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A major determinant of disease progression is increased peripheral blood proviral load (PVL), possibly via the accumulation of infected cells in the central nervous system (CNS) creating a damaging inflammatory response. Current therapeutic approaches that focus on reducing either cell proliferation, viral replication, or tissue invasion are still unsatisfactory. Contrasting with these inhibitory strategies, we evaluated the efficacy of a novel approach aimed, paradoxically, at activating viral gene expression to expose virus-positive cells to the host immune response. We used valproate (VPA), a histone deacetylase inhibitor that has been used for decades as a chronic, safe treatment for epileptic disorders. Based on in vitro and in vivo data, we provide evidence that transient activation of the latent viral reservoir causes its collapse, a process that may alleviate the condition of HAM/TSP. This represents the first such approach to treating HAM/TSP, using gene activation therapy to tilt the host-pathogen balance in favor of an existing antiviral response. This trial is registered at http://clinicaltrials.gov/as no. NCT00519181.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227
Nagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C. R., Izumo, S., et al. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114225 · Cited by 694
Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150
Interferon‐β1a therapy in human T‐lymphotropic virus type I–associated neurologic disease
Oh, U., Yamano, Y., Mora, C. A., Ohayon, J., Bagnato, F., Butman, J. A., Dambrosia, J., Leist, T. P., McFarland, H., & Jacobson, S. (2005) · Annals of Neurology · doi:10.1002/ana.20429 · Cited by 74
Saito, M., Nakagawa, M., Kaseda, S., Matsuzaki, T., Jonosono, M., Eiraku, N., Kubota, R., Takenouchi, N., Nagai, M., Furukawa, Y., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/380101 · Cited by 52 · cited 2×
“(D) The percentages of apoptotic CD4 cells were measured in samples from the 3 HAM/TSP patients (1-3) and 3 noninfected controls (4-6) cultivated without ( ) or with ( ) 2 mM VPA.”
Method
Cited by
HTLV-1-associated myelopathy/tropical spastic paraparesis
Bangham, C. R. M., Araujo, A., Yamano, Y., & Taylor, G. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.12 · Cited by 279
Matsuoka, M., & Jeang, K.-T. (2011) · Oncogene · doi:10.1038/onc.2010.537 · Cited by 268
Preventive and Therapeutic Strategies for Bovine Leukemia Virus: Lessons for HTLV
Rodríguez, S. M., Florins, A., Gillet, N., De Brogniez, A., Sánchez-Alcaraz, M. T., Boxus, M., Boulanger, F., Gutiérrez, G., Trono, K., Alvarez, I., et al. (2011) · Viruses · doi:10.3390/v3071210 · Cited by 196
“In primary cells freshly isolated from HAM/TSP patients, VPA induced hyperacetylation, triggered viral expression and was proapoptotic [159,162,163].”
BackgroundSelf-citationFutsch, N., Mahieux, R., & Dutartre, H. (2017) · Viruses · doi:10.3390/v10010001 · Cited by 155
“One study reported an efficient 24-fold decrease in the proviral load after 3 months of treatment [197], while another one reported no proviral load decrease after 2 years of treatment, nor any difference in the CD8+ lysis efficiency [196].”
BackgroundSafety of long-term treatment of HAM/TSP patients with valproic acid
Olindo, S., Belrose, G., Gillet, N., Rodriguez, S., Boxus, M., Verlaeten, O., Asquith, B., Bangham, C., Signaté, A., Smadja, D., et al. (2011) · Blood · doi:10.1182/blood-2011-04-349910 · Cited by 52
“Real time quantification performed in the Virology-Immunology reference laboratory of Fort-de-France indicated that administration of VPA to HAM/TSP patients led to a decrease in their PVL a few weeks after initiation of treatment [6].”
BackgroundMethodSelf-citation
Metadata
- Authors
- Lezin, A., Gillet, N., Olindo, S., Signaté, A., Grandvaux, N., Verlaeten, O., Belrose, G., de Carvalho Bittencourt, M., Hiscott, J., Asquith, B., Burny, A., Smadja, D., Césaire, R., & Willems, L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-11-15
- Volume
- 110
- Issue
- 10
- Pages
- 3722-3728
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2137328701
- Cited by
- 93
- References
- 5
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone deacetylase–mediated transcriptional activation reduces proviral loads in HTLV-1–associated myelopathy/tropical spastic paraparesis patients. https://app.cochat.ai/papers/10.1182/blood-2007-04-085076
- The paper
- Lezin, A., Gillet, N., Olindo, S., Signaté, A., Grandvaux, N., Verlaeten, O., Belrose, G., de Carvalho Bittencourt, M., Hiscott, J., Asquith, B., Burny, A., Smadja, D., Césaire, R., & Willems, L. (2007). Histone deacetylase–mediated transcriptional activation reduces proviral loads in HTLV-1–associated myelopathy/tropical spastic paraparesis patients. Blood. https://doi.org/10.1182/blood-2007-04-085076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.